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AbstrACt
Introduction Large sample sizes are often required 
to detect statistically significant associations between 
pharmacogenetic markers and treatment response. Meta-
analysis may be performed to synthesise data from several 
studies, increasing sample size and consequently power 
to detect significant genetic effects. However, performing 
robust synthesis of data from pharmacogenetic studies 
is often challenging due to poor reporting of key data 
in study reports. There is currently no guideline for the 
reporting of pharmacogenetic studies. The aim of this 
project is to develop the STrengthening the Reporting Of 
Pharmacogenetic Studies (STROPS) guideline. The STROPS 
guideline will facilitate the conduct of high-quality meta-
analyses and thus improve the power to detect genetic 
associations.
Methods and analysis We will establish a preliminary 
checklist of reporting items to be considered for inclusion 
in the guideline. We will then conduct a Delphi survey 
of key stakeholder groups to gain consensus opinion on 
which reporting items to include in the final guideline. 
The Delphi survey will consist of two rounds: the first 
round will invite participants to score items from the 
preliminary checklist and to suggest additional relevant 
items; the second round will provide feedback from the 
previous round and invite participants to re-score the 
items. Following the second round, we will summarise 
the distribution of scores for each item, stratified by 
stakeholder group. The Steering Committee for the project 
and representatives from the key stakeholder groups will 
meet to consider the results of the Delphi survey and 
to finalise the list of reporting items. We will then draft, 
pilot-test and publish the STROPS reporting guideline and 
accompanying explanatory document.
Ethics and dissemination The University of Liverpool 
Ethics Committee has confirmed ethical approval for 
this study (reference: 3586). Dissemination activities will 
include presenting the reporting guideline at conferences 
relevant to pharmacogenetic research.
IntroduCtIon
Pharmacogenetic studies investigate associa-
tions between genetic variants and treatment 
response for a particular drug of interest, in 
terms of both benefits (therapeutic effect) 
and harms (adverse effects). The aim of 
performing such studies is to identify ways 
that drug efficacy may be maximised, and 
that toxicity may be minimised. If a signifi-
cant association between a genetic variant 
and a treatment response outcome is iden-
tified, patients may eventually be genotyped 
in clinical practice before being prescribed a 
certain treatment. The healthcare provider 
may then refer to the results of the genotyping 
test when determining whether to prescribe 
the drug, and if prescribed, the appropriate 
dosage of the drug. Such an approach is 
known as ‘personalised medicine’.
Outcomes from pharmacogenetic studies 
are often likely to be complex traits; genetic 
influence may be explained by several genetic 
variants each having only a small effect on 
outcome. Consequently, large sample sizes 
are typically required to detect statistically 
significant associations between a genetic 
variant and treatment response. Meta-anal-
ysis improves sample size and consequently 
increases the power to detect significant 
strengths and limitations of this study
 ► We will conduct our project using methodology pro-
posed by the EQUATOR (Enhancing the QUAlity and 
Transparency Of health Research) network for the 
development of reporting guidelines.
 ► The Delphi survey will enable us to gain information 
about the opinions of a wide group of participants.
 ► Our study design is limited by the fact that the con-
sensus meeting will involve only the six members of 
the Steering Committee and one or two represen-
tatives from the key stakeholder groups and will be 
conducted via conference call.
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genetic effects. However, significant differences are often 
observed between pharmacogenetic studies in terms of 
the genetic variants investigated, definition of genetic 
subgroups and outcomes, and assumptions made in 
the analyses for example about the underlying mode of 
inheritance. This can significantly reduce the number of 
studies available to contribute to a single meta-analysis. 
This problem is compounded by poor reporting of key 
data in study reports. For example, if the authors of a 
particular study do not report the number of participants 
in each genotype group and outcomes for each genotype 
group separately, it may not be possible for researchers 
conducting a systematic review to include this study in a 
meta-analysis. Furthermore, lack of reporting of partic-
ipants’ ethnic backgrounds can also severely hinder 
investigations of heterogeneity, which form a key part 
of any systematic review and/or meta-analysis. Genetic 
associations are likely to vary according to ethnicity; it is 
therefore recommended that meta-analyses are always 
stratified by ethnicity, and pooling of results should only 
be performed if effect estimates for different ethnic 
groups appear sufficiently similar.1
The aim of our project is to develop a guideline for the 
reporting of pharmacogenetic studies and an explanatory 
document using methodology proposed by EQUATOR 
(Enhancing the QUAlity and Transparency Of health 
Research).2 Such a guideline would facilitate the conduct 
of high-quality systematic reviews and meta-analyses, thus 
improving power to detect genetic associations.
An explanation of the terms used in this proposal
Steering Committee
The panel consists of six members: Marty Richardson 
(researcher into meta-analysis of pharmacogenetic 
studies), Jamie Kirkham (researcher into consensus 
methodology and developer of reporting guidelines), 
Kerry Dwan (researcher into systematic review method-
ology), Derek Sloan (Senior Clinical Lecturer in Infec-
tious Diseases), Gerry Davies (Professor of Infection 
Pharmacology) and Andrea Jorgensen (researcher into 
statistical methods for pharmacogenetics, including 
evidence synthesis methods).
delphi participants
Participants in the Delphi survey.
MEthods And AnAlysIs
We (the Steering Committee) will develop the guideline 
for pharmacogenetic studies in five stages:
1. Establish a preliminary checklist of reporting items to 
be considered for inclusion in the reporting guideline 
for pharmacogenetic studies (stage 1).
2. Conduct a Delphi survey to gain consensus opinion on 
reporting items to be considered within a reporting 
guideline for pharmacogenetic studies (stage 2).
3. Hold a consensus meeting to consider the results of 
the Delphi survey and to finalise the list of items for 
the reporting guideline (stage 3).
4. Develop and publish a high-quality reporting guide-
line and a detailed explanatory document (stage 4).
5. Dissemination activities to raise awareness of the pub-
lished guideline, including presenting the guideline at 
relevant conferences (stage 5).
stage 1: Preliminary checklist of reporting items
We will establish a preliminary checklist of reporting 
items by:
i. Including items from existing relevant guidelines: 
Existing relevant guidelines will be identified by 
considering all guidelines listed on the EQUATOR 
website,3 under the clinical area of genetics. Two au-
thors (MR and ALJ) will assess existing guidelines to 
be relevant if they are applicable to pharmacogenetic 
studies from their experience of reviewing and un-
dertaking meta-analyses of pharmacogenetic studies. 
We will include items from these existing guidelines 
in our preliminary checklist if they ensure transpar-
ency of reporting of pharmacogenetic studies and 
consequently will enable future evidence synthesis.
ii. Supplementing this list with any additional items 
thought to be important: Additional items will be 
identified by consideration of the quality assessment 
checklist for pharmacogenetic studies developed by 
Jorgensen and Williamson,4 and through discussion 
among the Steering Committee.
iii. Providing an explanation and/or example of each 
reporting item: One author (MR) will draft the ex-
planation and/or example for each reporting item. 
This will ensure that each reporting item is clear to 
participants in the Delphi survey.
All members of the Steering Committee will review and 
approve this preliminary list of reporting items and expla-
nations/examples before the Delphi survey begins.
stage 2: delphi survey
Design
The Delphi process will consist of two rounds of electron-
ic-based survey, response and feedback. The first round 
survey will include scoring of reporting guideline items 
from the preliminary list formed at stage 1 and will invite 
additional items not included in this list. A second round 
survey will then be undertaken providing feedback from 
the previous round and inviting participants to re-score 
these items. Any additional reporting items identified by 
participants in the first round will be included for scoring 
by participants in the second round of the Delphi process.
Participants
We will invite three groups of stakeholders to participate 
in the Delphi survey. Stakeholder groups will be chosen 
to encompass all aspects of pharmacogenetic research.
1. Those who undertake primary pharmacogenetic 
research
We will ask members of pharmacogenetic networks, 
such as the Pharmacogenomics Research Network 
(PGRN) and the UK Pharmacogenetics and Stratified 
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Medicine Network, to participate in our Delphi survey. 
We will perform searches to identify these networks 
and contact experts in the field to ensure that all major 
networks across the globe are identified.
2. Those who systematically review pharmacogenetic 
research data
We will email the contact authors of systematic reviews 
of pharmacogenetic studies identified by searching 
PubMed, using appropriate search terms such as ‘pharma-
cogenetics’, ‘pharmacogenomics’, ‘systematic review’ and 
‘meta-analysis’. We will consult an information specialist 
(Eleanor Kotas) to design the search strategy. We will ask 
these authors to complete the survey if they participated 
in the data extraction and/or data synthesis of the review, 
and we will also ask this author to forward the survey on 
to other authors who participated in the data extraction 
and/or data synthesis.
3. Those who publish pharmacogenetic research
We will identify these individuals by contacting the 
editors-in-chief of key pharmacogenetic journals. We will 
perform searches to identify key journals, using search 
terms ‘pharmacogenetics’, ‘pharmacogenomics’, ‘preci-
sion medicine’, ‘personalised/personalized medicine’. 
We will also consider journals listed on the ‘The SCImago 
Journal & Country Rank’ portal5 under the subject cate-
gory ‘Genetics’. We will contact experts in the field to 
ensure that we have not missed any key journals. We will 
ask the editors-in-chief to participate in the survey them-
selves and also to forward the survey on to editors at their 
journal.
The decision of how many individuals to invite to 
complete a Delphi survey is not based on statistical power 
and often must be a pragmatic choice.6 Generally, there 
should be good representation of experts from the key 
stakeholder groups who have a deep understanding of 
the relevant issues. Our aim is to maximise the number of 
participants who complete the Delphi survey to ensure that 
the total number of participants within each stakeholder 
group is sufficiently large to yield a meaningful statistical 
analysis.
For the stakeholder group of primary researchers, we 
are confident that a sufficiently large number of individ-
uals will complete the survey; two of the networks (the 
PGRN network and the UK Pharmacogenetics and Strati-
fied Medicine Network) whose members we will invite to 
complete the survey together have over 1000 members. For 
the stakeholder groups of systematic reviewers and journal 
editors, we hope that the snowballing technique, that is 
asking review authors and editors-in-chief to forward the 
survey on to other individuals, will ensure that the number 
of participants in these groups is sufficiently large.
recruitment process and ethical considerations
We will email the individuals listed above with informa-
tion about the STROPS project and the Delphi process 
and an invitation to complete round 1 of the Delphi 
survey within 3 weeks (see online supplementary file 1). 
We will inform invitees that participation in the survey is 
optional and that we will assume informed consent if an 
invitee responds to round 1 of the survey. We will inform 
invitees that all data will be anonymised, and we will allo-
cate a unique identification number to each participant 
in the Delphi survey. When registering for the study on 
the survey website, participants will also be asked to tick a 
box if they agree to participate in the study.
We will send a reminder email at the end of the second 
week to prompt completion of the survey. We will not be 
able to send a reminder email to individuals who received 
forwarded invitations, as we will not have contact infor-
mation for these individuals at this stage. All participants 
who complete the first round of the Delphi survey will 
be invited to participate in the second round. However, 
we will inform invitees that completion in the first round 
does not necessitate completion in the second round, 
and we will remind participants of the first round that this 
is the case, when we invite them to complete the second 
round.
If attrition rates (the degree of non-response to the 
second round of the survey) are high, either for a partic-
ular stakeholder group or overall, then we will adopt strat-
egies to increase response rates. Generally, a response 
rate of around 80% for the second round of a Delphi 
survey can be considered satisfactory in most scenarios.6 
Strategies for increasing response rates to round 2 may 
include sending personalised reminder emails, offering 
acknowledgement in the published reporting guideline 
and extending the period of time for which the second 
round is open.
If participants who do not respond to round 2 have 
different opinions to participants from the same stake-
holder group who complete both rounds, then attrition 
bias has occurred and this will affect the results of the 
Delphi survey. If response rates to round 2 are less than 
80%, we will investigate the risk of attrition bias. We will 
calculate average round 1 scores for each participant, and 
then plot these scores according to whether participants 
completed round 2 or not for each stakeholder group. 
We will visually examine these plots to assess the likeli-
hood of attrition bias.
Participant characteristics
We will ask participants to provide their name, email 
address and their consent to be acknowledged as a partici-
pant in the Delphi survey in publications arising from this 
project. Demographic data regarding the participant’s 
profession and previous involvement with reporting 
guideline development will be collected; all demographic 
data will be anonymised.
delphi scoring
Participants will be asked to score each of the reporting 
guideline items listed using a scale of 1 to 9, with 1 to 3 
labelled ‘not important for inclusion in the guideline’, 4 
to 6 labelled ‘important but not critical for inclusion in 
the guideline’ and 7 to 9 labelled ‘critical for inclusion 
into the guideline’.7 Participants will also be given the 
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option to score a reporting guideline item as ‘unable to 
score’ if they are unable to offer an opinion as to whether 
the item is important or not.
software
The Delphi survey will be conducted using DelphiMan-
ager, a web-based system designed by the COMET Initia-
tive (http://www. comet- initiative. org/ delphimanager/) 
to facilitate the building and management of Delphi 
surveys.
delphi round 1
Reporting guideline items will be presented in the order 
in which they would be addressed in the pharmacogenetic 
study report and will be grouped under relevant head-
ings (ie, title and abstract, introduction, methods, results, 
discussion and other information). Participants will be 
asked to score each item as described previously. Partici-
pants will also be given the chance to add items that they 
believe should be included in the reporting guideline.
round 1 analysis
For each item, the number of participants who have 
scored the item and the distribution of scores will be 
summarised. Participants who scored an item as ‘unable 
to score’ will be excluded from the analysis for that partic-
ular item. We will review all additional guideline reporting 
items listed by participants to ensure that they are not 
covered by the existing list of reporting guideline items. 
Additional reporting guidelines items that are not already 
covered will undergo formal review and discussion by the 
Steering Committee, and if appropriate, will be added to 
the list of reporting guideline items presented in round 2.
delphi round 2
In round 2, each participant who participated in round 
1 will be shown the number of respondents and distri-
bution of scores for each item from round 1, for each 
stakeholder group separately. Participants will also be 
reminded how they personally scored each item in round 
1. Participants will be asked to consider the responses 
from other Delphi participants and to re-score the items.
In addition, if a participant changes their score from 
‘not critical’ in round 1 to ‘critical’ in round 2 or from 
‘critical’ in round 1 to ‘not critical’ in round 2, they will 
be asked to provide their reasoning for this change.
Additional items identified as part of round 1 will be 
scored by participants in round 2.
round 2 analysis
For each item, the number of respondents and the distri-
bution of scores will be summarised. Participants who 
scored an item as ‘unable to score’ will be excluded from 
the analysis for that particular item. We will assess the 
possibility of attrition bias occurring by comparing item 
scores from participants who completed round 1 only, to 
item scores from participants who completed both round 
1 and round 2. We will also examine changes in scores 
between rounds and summarise the reasons given for 
changes from ‘critical’ to ‘non-critical’ and vice versa.
Consensus definition
Guideline reporting items will be prioritised if at least 
70% of participants score them as ‘critical’. The rationale 
for this threshold is that consensus that an item ought 
to be included in the reporting guideline requires agree-
ment by the majority regarding the critical importance 
of the outcome. This threshold for consensus has been 
used previously in the development of the COS-STAR 
reporting guideline.8
stage 3: Consensus meeting
The Steering Committee and one or two representatives 
from each stakeholder group will meet to consider the 
results of the Delphi survey and to finalise the list of items 
for the draft reporting guideline. Representatives from 
each stakeholder group must have completed both rounds 
of the Delphi survey. Furthermore, we aim to include at 
least one non-UK representative from each stakeholder 
group in the consensus meeting. The meeting will be 
conducted via conference call.
At the meeting, MR will present a summary of the 
results of how each stakeholder group had scored each 
reporting guideline item (from stage 2), and the number 
of stakeholder groups who achieved consensus. Meeting 
attendees will discuss each reporting guideline item in 
turn and will make a decision on whether to include the 
item in the reporting guideline or not. Items that reached 
consensus from all stakeholder groups in the Delphi 
survey will be considered first. Each remaining item will 
then be considered in turn according to the number of 
stakeholder groups where consensus was achieved, that 
is, the next batch of items to be considered will be those 
that reached consensus in all but one stakeholder group.
stage 4: development and publication of reporting guideline 
and explanatory document
We will draft the initial reporting guideline and the 
explanatory document concurrently. The purpose of the 
explanatory document is to provide the meaning and 
rationale for each reporting item alongside examples 
of good reporting practice. For each item, we will also 
document the origin of the item (Steering Committee 
or Delphi participants) and the degree of consensus 
achieved from the Delphi survey.
We will pilot-test the draft reporting guideline with 
researchers who are yet to publish the findings of their 
pharmacogeneticstudy and with researchers who have 
already published a pharmacogenetic study. We will iden-
tify these individuals by contacting pharmacogenetic 
researchers based at the University of Liverpool and by 
contacting authors of published pharmacogenetic studies 
listed on PubMed. We will incorporate feedback on the 
content, format and usefulness of the guideline from 
these researchers in the final reporting guideline.
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stage 5: dissemination of the reporting guideline
Dissemination activities will include presenting the final 
reporting guideline at conferences relevant to pharmaco-
genetic research.
Patient and public involvement statement
The STROPS guideline will be developed without patient 
involvement. Patients were not invited to contribute to 
the writing or editing of this document for readability or 
accuracy.
dIsCussIon
We plan to conduct our project using robust method-
ology for developing reporting guidelines proposed by 
the EQUATOR network.2 Using such methodology will 
ensure that the resulting reporting guideline is useful and 
widely disseminated. The EQUATOR approach includes 
a face-to-face consensus meeting, which follows the 
Delphi survey. This meeting often involves the steering 
group and a selection of stakeholders who took part in 
the Delphi survey. Simera et al9 conducted a survey of 
authors of 37 reporting guidelines and reported that the 
median number of people participating in consensus 
meetings for these reporting guidelines was 22. Due to a 
lack of funding for this project to cover travel and accom-
modation costs, we will be unable to arrange a face-to-
face consensus meeting including such a large number 
of participants. Our consensus meeting will only involve 
the members of the Steering Committee (n=6) and one 
or two representatives of the key stakeholder groups, 
and the meeting will be conducted via conference call. 
We will invite a large, international and multidisciplinary 
cohort to participate in the Delphi survey, so that meeting 
attendees are able to base their decisions on the opinions 
of this wider cohort.
We will prioritise items for inclusion in the guideline 
if at least 70% of participants score them as ‘critical’. 
Although the choice of this threshold is somewhat subjec-
tive, pre-specification of the threshold in this protocol 
ought to provide assurance that we will not define 
consensus in a post-hoc way, and therefore our own opin-
ions will not bias the results of the Delphi survey.10
There is currently no guideline for the reporting of 
pharmacogenetic studies that has been developed using 
a widely accepted robust methodology. The final guide-
line will not only improve the transparency of reporting 
of pharmacogenetic studies but also facilitate the conduct 
of high-quality systematic reviews and meta-analyses, and 
thus improve the power to detect genetic associations. 
With the increasing number of meta-analyses of phar-
macogenetic studies that are being undertaken, it is 
important that reporting of key data in study reports is 
improved in order to allow robust synthesis of the studies.
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